annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 46F A prospective trial of prophylaxis and treatment (P�T) of acute tumor lysis
syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children
and adolescents (C�A) with intermediate- (Group B) and high-risk (Group C)
mature B-NHL: A Children’s Oncology Group report. (Abstract #9572)
S. Goldman, J. C. Lynch, L. Harrison, M. S. Cairo
Brd. 46G High-dose methotrexate in the treatment of acute lymphoblastic leukemia:
Toxicity profile and comparison of tolerability betwen two dosage schedules.
(Abstract #9573)
A. R. Warrier, R. Rejiv, D. Biswajit, S. G. Ramanan, T. G. Sagar
Brd. 46H T-cell lymphoblastic lymphoma in children and adolescents: The experience
of the Israel Society of Pediatric Hematology Oncology. (Abstract #9574)
M. W. Ben Arush, O. Beyar Katz, A. Ben Barak, G. Avrahami, R. Dvir,
J. Kapelushnik, H. Kaplinsky, S. Vilk Revel, I. Yaniv, S. Linn
Brd. 47A Risk-based outcome of childhood AML: Experience of National Guard
Hospital, Jeddah, Saudi Arabia. (Abstract #9575)
W. A. Jastaniah, T. M. Khattab, S. K. Felimban
Brd. 47B High frequency of Gilbert’s syndrome in ETV6/RUNX1-positive childhood
acute lymphoblastic leukemia (ALL): Implications for etiology.
(Abstract #9576)
Y. Ravindranath, I. Brecht, J. Feldman, R. K. Severson, F. Nahhas, A. Nahar,
G. Goyette
Brd. 47C Clostridium difficile infection among children with cancer. (Abstract #9577)
E. Tai, L. C. Richardson, J. Townsend, E. Howard, C. McDonald
Brd. 47D Iterative anesthesia for radiation therapy in pediatric oncology: Safety of a
procedure using propofol alone. (Abstract #9578)
H. Sebban, L. Claude, C. Conter, V. Bachelot, P. Marec Bérard, P. Bachmann,
A. Daunizeau, C. De La Fouchardiere, C. Carrie
Brd. 47E Diagnosis of invasive fungal infections by RQ-PCR assay in pediatric acute
leukemia induction. (Abstract #9579)
S. Mandhaniya, S. Iqbal, S. K. Sharawat, I. Xess, S. Bakhshi
Brd. 47F Clinical pharmacokinetics (PK) and safety of high-dose (HD) methotrexate
(MTX) during induction therapy of pediatric patients younger than 3 years of
age with primary brain tumors. (Abstract #9580)
T. McKibbin, M. Tagen, J. C. Panetta, D. Ward, A. J. Gajjar, K. D. Wright,
A. Broniscer, C. F. Stewart
Brd. 47G Criteria defining the duration of chemoreduction with focal treatment in
retinoblastoma: A retrospective analysis. (Abstract #9581)
M. Beck Popovic, H. Abouzeid, M. Gaillard, M. Faouzi, A. Pica, A. Balmer,
F. Munier
279
SUNDAY